- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06268301
A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults
A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics, Safety, and Tolerability of Budesonide Oral Suspension in Healthy Adult Participants
Study Overview
Detailed Description
The drug being tested in this study is called budesonide. Budesonide oral suspension (BOS) is being tested in healthy adult participants. This study will determine whether the absorption of BOS will be altered if taken with food.
The study will enroll approximately 20 patients. The study will consist of two treatment sequences and two periods separated by a washout period of 2 days. Participants will be randomly assigned (by chance, like flipping a fair coin) to one of the two treatment sequences:
- Treatment Sequence 1: Participants will receive 2 mg BOS orally on Day 1 of Period 1 in fasted condition (Treatment A). Two days later, participants will receive 2 mg BOS orally on Day 1 of Period 2 in fed condition (Treatment B).
- Treatment Sequence 2: Participants will receive 2 mg BOS orally on Day 1 of Period 1 in fed condition (Treatment B). Two days later, participants will receive 2 mg BOS orally on Day 1 of Period 2 in fasted condition (Treatment A).
This single center trial will be conducted in the United States. Participation in the study is up to approximately 34 days. Participants will visit the clinic approximately three days after last dose of study drug for a follow-up assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting.
- Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kilograms per meters squared (kg/m^2) at the screening visit.
Exclusion Criteria:
- Presence of any active infection at the screening visit or check-in.
- Positive urine drug or alcohol results at the screening visit or check-in.
- Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit.
Participant is unable to refrain from or anticipates the use of:
- Any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dosing. Medication listed as part of acceptable birth control methods, hormone replacement therapy, and thyroid hormone replacement medication will be allowed.
- Any drugs known to be moderate or strong inducers of cytochrome P450 (CYP) 3A4 enzymes and/or p-glycoprotein (P-gp), including St. John's Wort, for 28 days prior to the first dosing. Appropriate sources (e.g., Flockhart Table™) will be consulted to confirm lack of pharmacokinetic (PK) /pharmacodynamic interaction with the study drug.
- Participant is lactose intolerant.
- Donation of blood or significant blood loss within 56 days prior to the first dosing.
- Plasma donation within 7 days prior to the first dosing.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence 1: BOS 2 mg Fasted, then Fed
Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fasted condition (Treatment A).
Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fed condition (Treatment B).
|
Budesonide oral suspension
Other Names:
|
Experimental: Sequence 2: BOS 2 mg Fed, then Fasted
Participants will receive 2 mg BOS, single dose, orally on Day 1 of Period 1 under fed condition (Treatment B).
Two days later, participants will receive 2 mg BOS single dose, orally on Day 1 of Period 2 under fasted condition (Treatment A).
|
Budesonide oral suspension
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Observed Concentration (Cmax)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants who Experience at Least one Treatment Emergent Adverse Event (TEAE) by Severity, Serious Adverse Events (SAE) and Death
Time Frame: From screening up to the end of study (EOS) (Up to approximately 34 days)
|
An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (e.g., a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug.
A TEAE is defined as an adverse event with an onset that occurs for a non-specified period of time after receiving study drug.
An SAE is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that may require an intervention to prevent above items and expose the participant to danger.
|
From screening up to the end of study (EOS) (Up to approximately 34 days)
|
Number of Participants With Clinically Significant Abnormal Vital Sign Values
Time Frame: From screening up to EOS (Up to approximately 34 days)
|
Vital signs will include body temperature, respiratory rate, blood pressure, and pulse rate evaluations.
|
From screening up to EOS (Up to approximately 34 days)
|
Number of Participants With Clinically Significant Abnormal Clinical Laboratory Values
Time Frame: From screening up to EOS (Up to approximately 34 days)
|
Clinical laboratory parameters will include hematology, clinical chemistry, serum immunoglobulin and urinalysis tests.
|
From screening up to EOS (Up to approximately 34 days)
|
Area Under the Concentration-time Curve From Time 0 to 12 Hours (AUC0-12)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 12 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 12 hours) post-dose
|
|
Area Under the Curve From the Last Quantifiable Concentration to Infinity Expressed as a Percentage of AUC∞ (AUCextrap%)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Time to First Occurrence of Cmax (tmax)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Lag Time to First Quantifiable Concentration (tlag)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Terminal Disposition Phase Half-life (t1/2z)
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Terminal Disposition Phase Rate Constant (λz).
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Apparent Clearance (CL/F) Calculated Using the Observed Value of the Last Quantifiable Concentration
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
|
Apparent Volume of Distribution During the Terminal Disposition Phase (Vz/F) Calculated Using the Observed Value of the Last Quantifiable Concentration
Time Frame: Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Period 1 and 2: Days 1 and 2 pre-dose and at multiple timepoints (up to 24 hours) post-dose
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAK-721-1003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on Budesonide
-
West Penn Allegheny Health SystemCompleted
-
University of MiamiAstraZenecaCompleted
-
Meir Medical CenterUnknown
-
Research in Real-Life LtdOrion Corporation, Orion PharmaCompleted
-
Aquilon Pharmaceuticals S.A.Completed
-
St. Paul's Hospital, CanadaUnknown
-
AstraZenecaCompleted
-
Dr. Falk Pharma GmbHCompletedEosinophilic EsophagitisGermany